Oliver J Ott1, Vratislav Strnad2, Wilhelm Stillkrieg2, Wolfgang Uter3, Matthias W Beckmann4, Rainer Fietkau2. 1. Department of Radiation Oncology, University Hospital Erlangen, Universitätsstraße 27, 91054, Erlangen, Germany. oliver.ott@uk-erlangen.de. 2. Department of Radiation Oncology, University Hospital Erlangen, Universitätsstraße 27, 91054, Erlangen, Germany. 3. Dept. of Medical Informatics, Biometry and Epidemiology, University Erlangen-Nuremberg, Erlangen, Germany. 4. Dept. of Gynecology, University Hospital Erlangen, Erlangen, Germany.
Abstract
BACKGROUND AND PURPOSE: To evaluate the feasibility and efficacy of external beam three-dimensional (3D) conformal accelerated partial breast irradiation (APBI) for selected patients with early breast cancer. PATIENTS AND METHODS: Between 2011 and 2016, 72 patients were recruited for this prospective phase 2 trial. Patients were eligible for APBI if they had histologically confirmed breast cancer or pure ductal carcinoma in situ (DCIS), a tumor diameter ≤3 cm, clear resection margins ≥2 mm, no axillary lymph node involvement, no distant metastases, tumor bed clips, and were aged ≥50 years. Patients were excluded if mammography showed a multicentric invasive growth pattern, or if they had residual diffuse microcalcifications postoperatively, an extensive intraductal component, or vessel invasion. Patients received 3D conformal external beam APBI with a total dose of 38 Gy in 10 fractions in 1-2 weeks. The trial had been registered at the German Clinical Trials Register, DRKS-ID: DRKS00004417. RESULTS: Median follow-up was 25.5 months (range 1-61 months). Local control was maintained in 71 of 72 patients. The 3‑year local recurrence rate was 2.1% (95% confidence interval, CI: 0-6.1%). Early toxicity (grade 1 radiodermatitis) was seen in 34.7% (25/72). Late side effects ≥ grade 3 did not occur. Cosmetic results were rated as excellent/good in 96.7% (59/61). CONCLUSION: APBI with external beam radiotherapy techniques is feasible with low toxicity and, according to the results of the present and other studies, on the way to becoming a standard treatment option for a selected subgroup of patients.
BACKGROUND AND PURPOSE: To evaluate the feasibility and efficacy of external beam three-dimensional (3D) conformal accelerated partial breast irradiation (APBI) for selected patients with early breast cancer. PATIENTS AND METHODS: Between 2011 and 2016, 72 patients were recruited for this prospective phase 2 trial. Patients were eligible for APBI if they had histologically confirmed breast cancer or pure ductal carcinoma in situ (DCIS), a tumor diameter ≤3 cm, clear resection margins ≥2 mm, no axillary lymph node involvement, no distant metastases, tumor bed clips, and were aged ≥50 years. Patients were excluded if mammography showed a multicentric invasive growth pattern, or if they had residual diffuse microcalcifications postoperatively, an extensive intraductal component, or vessel invasion. Patients received 3D conformal external beam APBI with a total dose of 38 Gy in 10 fractions in 1-2 weeks. The trial had been registered at the German Clinical Trials Register, DRKS-ID: DRKS00004417. RESULTS: Median follow-up was 25.5 months (range 1-61 months). Local control was maintained in 71 of 72 patients. The 3‑year local recurrence rate was 2.1% (95% confidence interval, CI: 0-6.1%). Early toxicity (grade 1 radiodermatitis) was seen in 34.7% (25/72). Late side effects ≥ grade 3 did not occur. Cosmetic results were rated as excellent/good in 96.7% (59/61). CONCLUSION: APBI with external beam radiotherapy techniques is feasible with low toxicity and, according to the results of the present and other studies, on the way to becoming a standard treatment option for a selected subgroup of patients.
Entities:
Keywords:
Breast cancer; Breast conserving surgery; Radiotherapy; Survival; Toxicity
Authors: T Jonathan Yang; Randa Tao; Paula H M Elkhuizen; Corine van Vliet-Vroegindeweij; Guang Li; Simon N Powell Journal: Radiother Oncol Date: 2013-06-24 Impact factor: 6.280
Authors: Chirag Shah; John Vito Antonucci; John Ben Wilkinson; Michelle Wallace; Mihai Ghilezan; Peter Chen; Kenneth Lewis; Christina Mitchell; Frank Vicini Journal: Radiother Oncol Date: 2011-04-15 Impact factor: 6.280
Authors: Ivo A Olivotto; Timothy J Whelan; Sameer Parpia; Do-Hoon Kim; Tanya Berrang; Pauline T Truong; Iwa Kong; Brandy Cochrane; Alan Nichol; Isabelle Roy; Isabelle Germain; Mohamed Akra; Melanie Reed; Anthony Fyles; Theresa Trotter; Francisco Perera; Wayne Beckham; Mark N Levine; Jim A Julian Journal: J Clin Oncol Date: 2013-07-08 Impact factor: 44.544
Authors: Csaba Polgár; Tibor Major; János Fodor; Zoltán Sulyok; András Somogyi; Katalin Lövey; György Németh; Miklós Kásler Journal: Radiother Oncol Date: 2010-02-22 Impact factor: 6.280
Authors: Kathrin Dellas; Reinhard Vonthein; Jörg Zimmer; Stefan Dinges; Alexander D Boicev; Peter Andreas; Dorothea Fischer; Cornelia Winkler; Andreas Ziegler; Jürgen Dunst Journal: Strahlenther Onkol Date: 2014-04-16 Impact factor: 3.621